Opinion|Videos|November 17, 2026

Managing Drug Interactions and Acid Suppression

Estelamari Rodriguez, MD, MPH, reviews drug interactions and administration factors that influence adherence to ROS1 tyrosine kinase inhibitors in ROS1-positive non-small cell lung cancer (NSCLC).

Estelamari Rodriguez, MD, MPH, reviews drug interactions and administration factors that influence adherence to ROS1 tyrosine kinase inhibitors in ROS1-positive non-small cell lung cancer (NSCLC). She advises checking each label for proton pump inhibitor (PPI) interactions, empty-stomach requirements, and pill burden, and favors once-daily regimens without interactions that fit patients' routines. Dr. Rodriguez finds most patients highly adherent because they feel better quickly on therapy; however, she asks about vitamins and supplements that may interact through cytochrome P450 liver enzymes. Matthew A. Gubens, MD, MS, credits pharmacy colleagues with running interaction databases and guiding patients. Ana I. Velázquez Mañana, MD, MSc, notes that PPIs affect the absorption of all of these agents, including taletrectinib. She describes widespread and often unnecessary PPI use, partly because they are available over the counter, and recommends first assessing whether a patient needs one. When acid suppression is necessary, she works with gastroenterology or primary care to select shorter-acting antacids that minimize the effect on drug absorption.


Related to this article